| Literature DB >> 32801801 |
Zhenguo Wang1, Xiaojun Hu2, Zhonghe Li3, Huitao Zhang2, Changli Tu1, Yiming Wang4, Pengfei Pang2, Xiaobin Zheng1, Yingjian Liang1, Hong Shan2, Jing Liu1.
Abstract
METHODS: Forty-four COVID-19 patients (severe/critical: N = 8, non-severe: N = 36) were examined by next generation sequencing (NGS) of nasopharyngeal test paper to observe the effect of novel coronavirus infection to the microbial composition in upper airway.Entities:
Keywords: SARS-CoV-2; microbial composition; next generation sequencing; NGS; upper airway
Year: 2020 PMID: 32801801 PMCID: PMC7406177 DOI: 10.2147/IDR.S259984
Source DB: PubMed Journal: Infect Drug Resist ISSN: 1178-6973 Impact factor: 4.003
Demographics and Clinical Characteristics of COVID-19 Patients
| Characteristic | Total (n = 44) | Severe/Critical (n = 8) | Non-Severe (n = 36) | p value |
|---|---|---|---|---|
| Age, years | 54(3–77) | 62.5(54–77) | 44(3–71) | 0.008* |
| Gender Male | 21(47.7) | 5(62.5) | 16(44.4) | 0.35 |
| Female | 23(52.3) | 3(37.5) | 20(45.6) | |
| Fever | 29(65.9) | 7(87.5) | 22(61.1) | 0.15 |
| Cough | 18(40.9) | 3(37.5) | 15(41.7) | 0.83 |
| Fatigue | 5(11.4) | 3(37.5) | 2(5.5) | 0.01* |
| Nasal discharge | 2(4.5) | 0(0) | 2(5.5) | 0.49 |
| Pain (headache/sore throat/muscle aches, etc) | 9(20.4) | 2(25) | 7(19.4) | 0.72 |
| T, °C | 37.0(36.5–37.8) | 37.7(37.3–38.0) | 36.8(36.5–37.7) | 0.04* |
| Underlying diseases(N/Y) | 16(36.4) | 5(62.5) | 11(30.5) | 0.09 |
| Circulatory diseases (hypertension, coronary heart disease) | 7(15.9) | 2(25) | 5(13.9) | 0.44 |
| Respiratory basic diseases (chronic bronchitis, lung cancer) | 3(6.8) | 2(25) | 1(2.8) | 0.02* |
| Endocrine system basic diseases (diabetes) | 3(6.8) | 2(25) | 1(2.8) | 0.02* |
| Other systemic diseases (fractures, cerebral infarction, etc.) | 5(11.4) | 1(12.5) | 4(11.1) | 0.91 |
| White blood cell count, ×109/L | 4.61(3.67–6.48) | 3.52(3.14–4.59) | 4.82(3.83–6.56) | 0.04* |
| Lymphocyte count, ×109/L | 1.60 (1.08–2.13) | 0.85(0.45–1.46) | 1.76(1.36–2.46) | 0.001* |
| Neutrophil count, ×109/L | 2.30(1.79–3.47) | 2.08(1.30–3.34) | 2.36(1.88–3.61) | 0.38 |
| Monocyte count, ×109/L | 0.47(0.37–0.66) | 0.34(0.26–0.52) | 0.49(0.40–0.71) | 0.06 |
| NLR | 1.78(0.4–9.38) | 2.16(0.74–9.38) | 1.70 (0.40–5.68) | 0.025* |
| PCT | 2(4.5) | 1(12.8) | 1(2.8) | 0.23 |
| CRP, mg/L | 2.45(0.56–7.62) | 22.0(8.68–42.5) | 1.15(0.48–5.06) | 0.001* |
| CD3(+) T lymphocytes,/ul | 1057(742.8–1561) | 565 (226.0–794.5) | 1162(891.3–1734) | 0.001* |
| CD3(+)CD4(+) T lymphocytes,/ul | 579(408.3–831.5) | 325(174.5–483.8) | 631.5(449.8–842.5) | 0.006* |
| CD3(+)CD8(+) T lymphocytes,/ul | 355(263.8–514.5) | 159(64.5–281.8) | 457.5(318.8–553.0) | 0.0002* |
| PaO2, mmHg | 99.9(86.6–105.0) | 91.1(75.7–101.2) | 101.0(89.1–105.3) | 0.12 |
| One or both lungs | 2(0–2) | 2(1–2) | 1(0–2) | 0.02* |
| Number of lung lobes (0–5) | 2next (0–5) | 5(1–5) | 1(0–5) | 0.001* |
| Ground glass lesions | 29(65.9%) | 7(87.5%) | 22(61.1%) | 0.15 |
| Consolidation | 7(15.9%) | 3(37.5%) | 4(11.1%) | 0.06 |
| Bronchial abnormalities | 4(9.1%) | 2(25%) | 2(5.5%) | 0.08 |
| Mediastinal lymph node enlargement | 1(2.3%) | 1(12.5%) | 0(0) | 0.04* |
| Pleural effusion | 1(2.3%) | 1(12.5%) | 0(0) | 0.04* |
Note: *P<0.05.
Abbreviations: T, temperature; NLR, neutrophil-to-lymphocyte ratio; PCT, procalcitonin; CRP, C-reactive protein; PaO2, arterial partial pressure of oxygen.
Figure 1The microbial composition of upper airway in patients with SARS-CoV-2 infection.
Notes: The percentage of cases with different kinds of bacteria (A), virus (B), fungus and atypical pathogens (C) detected by next generation sequencing of nasopharyngeal test paper was shown in this figure. *P<0.05, there was significant difference between severe and non-severe groups.